These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 21316006)

  • 1. Recent advances in the treatment of metastatic colorectal cancer in Taiwan.
    Lin YL; Yeh KH; Cheng AL
    J Formos Med Assoc; 2011 Jan; 110(1):1-3. PubMed ID: 21316006
    [No Abstract]   [Full Text] [Related]  

  • 2. [Conversion therapy for colorectal cancer].
    Sasaki N; Yoshino T
    Gan To Kagaku Ryoho; 2011 Nov; 38(11):1793-7. PubMed ID: 22164897
    [No Abstract]   [Full Text] [Related]  

  • 3. New possibilities in chemotherapy for colorectal cancer.
    Bekradda M; Cvitkovic E
    Ann Oncol; 1999; 10 Suppl 6():105-11. PubMed ID: 10676561
    [No Abstract]   [Full Text] [Related]  

  • 4. Recent developments on the integration of biologic agents with cytotoxic chemotherapy in the treatment of advanced colorectal cancer.
    Chu E
    Clin Colorectal Cancer; 2008 Dec; 7 Suppl 2():S46. PubMed ID: 19064405
    [No Abstract]   [Full Text] [Related]  

  • 5. Sequencing therapies: the role of targeted agents in metastatic colorectal cancer.
    Oestreicher P
    ONS Connect; 2007; 22(8 Suppl):37-8. PubMed ID: 17824557
    [No Abstract]   [Full Text] [Related]  

  • 6. Optimizing oxaliplatin-based therapy in metastatic colorectal cancer.
    Cassidy J
    Clin Adv Hematol Oncol; 2008 May; 6(5):360-1. PubMed ID: 18516025
    [No Abstract]   [Full Text] [Related]  

  • 7. Intensive chemotherapy of metastatic colorectal cancer: weighing between safety and clinical efficacy: Evaluation of Masi G, Loupakis F, Salvatore L, et al. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncol 2010;11:845-52.
    Bruera G; Ricevuto E
    Expert Opin Biol Ther; 2011 Jun; 11(6):821-4. PubMed ID: 21545334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regorafenib in metastatic colorectal cancer: optimal dosing and patient selection recommendations.
    Grothey A
    Clin Adv Hematol Oncol; 2015 Aug; 13(8):514-7. PubMed ID: 26351814
    [No Abstract]   [Full Text] [Related]  

  • 9. Review article: benefits and risks of chemotherapy in elderly patients with metastatic colorectal cancer.
    Mitry E; Rougier P
    Aliment Pharmacol Ther; 2009 Jan; 29(2):161-71. PubMed ID: 18945257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Should FOLFOXIRI plus bevacizumab Be the standard first-line therapy in metastatic colorectal cancer?
    Nipp RD; Ryan DP
    Oncologist; 2015 Mar; 20(3):236-8. PubMed ID: 25660156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Innovations in chemotherapy for metastatic colorectal cancer: an update of recent clinical trials.
    O'Neil BH; Goldberg RM
    Oncologist; 2008 Oct; 13(10):1074-83. PubMed ID: 18922828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapy induced hepatotoxicity in metastatic colorectal cancer: a review of mechanisms and outcomes.
    McWhirter D; Kitteringham N; Jones RP; Malik H; Park K; Palmer D
    Crit Rev Oncol Hematol; 2013 Nov; 88(2):404-15. PubMed ID: 23786843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple genetic polymorphisms in the prediction of clinical outcome of metastatic colorectal cancer patients treated with first-line FOLFOX-4 chemotherapy.
    Huang MY; Huang ML; Chen MJ; Lu CY; Chen CF; Tsai PC; Chuang SC; Hou MF; Lin SR; Wang JY
    Pharmacogenet Genomics; 2011 Jan; 21(1):18-25. PubMed ID: 21057378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of the efficacy of chemotherapy with oxaliplatin plus 5-fluorouracil by pretreatment with IL-2 subcutaneous immunotherapy in metastatic colorectal cancer patients with lymphocytopenia prior to therapy.
    Lissoni P; Brivio F; Fumagalli L; Di Fede G; Brera G
    In Vivo; 2005; 19(6):1077-80. PubMed ID: 16277025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metastatic colorectal cancer: treatment challenges and quality of life.
    Bottomley A
    Lancet; 2002 May; 359(9317):1537-8. PubMed ID: 12047959
    [No Abstract]   [Full Text] [Related]  

  • 16. Tenth anniversary of bevacizumab in colorectal cancer: has it fulfilled its promise?
    Salazar R; Grasselli J; Santos C; Tabernero J
    Future Oncol; 2014 Feb; 10(2):149-52. PubMed ID: 24490598
    [No Abstract]   [Full Text] [Related]  

  • 17. The use cetuximab after oxaliplatin-based chemotherapy in a patient with metastatic colorectal cancer.
    Malik Z; Eng C
    Clin Adv Hematol Oncol; 2007 Jan; 5(1 Suppl 1):4-7. PubMed ID: 17491584
    [No Abstract]   [Full Text] [Related]  

  • 18. Picking the right road for metastatic colorectal cancer patients.
    Overman M; Kopetz S
    Oncology (Williston Park); 2008 Nov; 22(13):1482-3. PubMed ID: 19227576
    [No Abstract]   [Full Text] [Related]  

  • 19. [First-line chemotherapy for unresectable and metastatic colorectal cancer].
    Satoh T
    Gan To Kagaku Ryoho; 2014 Nov; 41(11):1372-5. PubMed ID: 25577805
    [No Abstract]   [Full Text] [Related]  

  • 20. Individualizing therapy for metastatic colorectal cancer.
    Turja J; Grothey A
    Oncology (Williston Park); 2008 Nov; 22(13):1479-81. PubMed ID: 19227569
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.